Intravenous Antiarrhythmic Drugs: Newer Aspects of Therapy

Abbott, Joseph A.
April 1982
Angiology;Apr1982, Vol. 33 Issue 4, p251
Academic Journal
Discusses aspects of therapy for tachyarrhythmias. Clinical relevance of experimental antiarrhythmic drugs that may be infused intravenously; Purposes of using intravenous antiarrhythmic drugs; Prevention of potentially fatal arrhythmia.


Related Articles

  • tocainide.  // Davis's Drug Guide for Nurses, 10th edition;2007, p1157 

    This article presents a nurse's guide to the antiarrhytmic agent tocainide. Tocainide is indicated for the treatment of life-threatening ventricular arrhythmias, including multifocal and unifocal premature ventricular contractions and ventricular tachycardia. Tocainide works by suppressing...

  • Narrow-complex tachycardia. Giudici, Michael C.; Gumpert, Tamra J. // American Family Physician;3/1/1994, Vol. 49 Issue 4, p823 

    Reviews the pathophysiology, diagnosis and treatment of narrow-complex tachycardia. Types; Mechanism of tachyarrythmias; Factors influencing automaticity in tachyarrythmias; Antiarrthymic drug classification.

  • Pharmacologic management of cardiac arrhythmias. Gi-Byoung Nam // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;May2013, Vol. 56 Issue 5, p425 

    Management of cardiac arrhythmias involves antiarrhythmic drugs (AADs), catheter ablation, pacemakers, and implantable defibrillators. The effects of AADs are mediated by blocking various cardiac ion channels, mostly the cardiac sodium, calcium, or potassium channels. A simple classification of...

  • Lidocaine may block an ATP-dependent K+ channel. Dale, David C.; Federman, Daniel D. // Cortlandt Forum;12/20/97, Vol. 10 Issue 12, p20 

    Reports that class IB antiarrhythmic drugs are less powerful sodium ion (Na+) channel blockers than class IA drugs. Reason why class IB agents are less powerful.

  • Ablation of incessant orthodromic reciprocating tachycardia in a child with congenitally corrected transposition of great arteries and ebsteinoid malformation of left atrioventricular valve. Chandrakant Chavan; Hygriv Rao; Rajesh Badani; P. Raju; C. Narasimhan // Journal of Interventional Cardiac Electrophysiology;Nov2008, Vol. 23 Issue 2, p149 

    Abstract  We report about a patient with congenitally corrected transposition of the great arteries and ebsteinoid malformation of left atrioventricular (AV) valve who presented with incessant orthodromic atrioventricular reciprocating tachycardia due to a left posteroseptal accessory...

  • Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control? Yi-Gang Li; Hohnloser, Stefan H. // Journal of Cardiovascular Pharmacology & Therapeutics;Jun1998, Vol. 3 Issue 2, p185 

    The article discusses therapeutic alternatives for patients with persistent atrial fibrillation. It summarizes the present knowledge on this clinical problem with particular emphasis on issues such as efficacy of antiarrhythmic drugs to prevent recurrent atrial fibrillation, proarrhythmic...

  • Antiarrhythmic Drug Therapy for Atrial Fibrillation: Focus on Atrial Selectivity and Safety. Li, D.; Sun, H.; Levesque, P. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2009, Vol. 7 Issue 1, p64 

    Atrial fibrillation (AF) is a highly prevalent arrhythmia and responsible for significant morbidity, mortality and health care cost. The prevalence of AF is expected to increase markedly with the aging population. The use of conventional antiarrhythmic agents has been limited by potentially...

  • Assessment of the Inactivation Potential of Desethylamiodarone on Human CYP1A1. Elsherbiny, Marwa E.; El-Kadi, Ayman O. S.; Brocks, Dion R. // Drug Metabolism Letters;Jan2010, Vol. 4 Issue 1, p9 

    Desethylamiodarone was reported to inactivate human CYP1A1. To assess this, two protocols were implemented employing dilution and non-dilution of the preincubation mixture. Inactivation studies performed with diluted preincubation mixtures showed no inactivation of CYP1A1 by desethylamiodarone....

  • Rythmodan Retard.  // Royal Society of Medicine: Medicines;2002, p483 

    The article presents information on rhythmodan retard, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide. It is available as modified-release tablets.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics